BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Au WY, Cheung PP. Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ 2022;377:e069989. [PMID: 35640925 DOI: 10.1136/bmj-2022-069989] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 20.0] [Reference Citation Analysis]
Number Citing Articles
1 Li Y, Qin Y, Chen N, Ge L, Wang Q, Aboudou T, Han J, Hou L, Cao L, Li R, Li M, Mi N, Xie P, Wu S, Hu L, Li X, Song Z, Ji J, Zhang Z, Yang K. Use of traditional Chinese medicine for the treatment and prevention of COVID-19 and rehabilitation of COVID-19 patients: An evidence mapping study. Front Pharmacol 2023;14. [DOI: 10.3389/fphar.2023.1069879] [Reference Citation Analysis]
2 Kim J, Kim D, Baek K, Kim M, Kang BM, Maharjan S, Park S, Choi JK, Kim S, Kim YK, Park MS, Lee Y, Kwon HJ. Production of a Monoclonal Antibody to the Nucleocapsid Protein of SARS-CoV-2 and Its Application to ELISA-Based Detection Methods with Broad Specificity by Combined Use of Detector Antibodies. Viruses 2022;15. [PMID: 36680068 DOI: 10.3390/v15010028] [Reference Citation Analysis]
3 Nittayasoot N, Suphanchaimat R, Thammawijaya P, Jiraphongsa C, Siraprapasiri T, Ploddi K, Pittayawonganon C, Mahasirimongkol S, Tharmaphornpilas P. Real-World Effectiveness of COVID-19 Vaccines against Severe Outcomes during the Period of Omicron Predominance in Thailand: A Test-Negative Nationwide Case-Control Study. Vaccines (Basel) 2022;10. [PMID: 36560533 DOI: 10.3390/vaccines10122123] [Reference Citation Analysis]
4 Siemens W, Breuer C, Meerpohl JJ. Editorial. Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen 2022. [DOI: 10.1016/j.zefq.2022.11.008] [Reference Citation Analysis]
5 Yang L, Gong L, Wang P, Zhao X, Zhao F, Zhang Z, Li Y, Huang W. Recent Advances in Lipid Nanoparticles for Delivery of mRNA. Pharmaceutics 2022;14. [PMID: 36559175 DOI: 10.3390/pharmaceutics14122682] [Reference Citation Analysis]
6 Jiang J, Zhao S, Cheng C, Lin N, Li P, Ning X, Zhang S. Impact of COVID-19 pandemic on catheter ablation in China: A spatiotemporal analysis. Front Public Health 2022;10:1027926. [PMID: 36504945 DOI: 10.3389/fpubh.2022.1027926] [Reference Citation Analysis]
7 Ai J, Guo J, Zhang H, Zhang Y, Yang H, Lin K, Song J, Fu Z, Fan M, Zhang Q, Wang H, Zhao Y, He Z, Cui A, Zhou Y, Wu J, Zhou M, Yuan G, Kang B, Zhao N, Xu Y, Zhu M, Wang Y, Zhang Z, Jiang N, Qiu C, Xu C, Zhang W. Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling. Cell Discov 2022;8:114. [PMID: 36270988 DOI: 10.1038/s41421-022-00480-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Moisoglou I, Passali C, Tsiachri M, Galanis P. Predictors of COVID-19 Vaccine Uptake in Teachers: An On-line Survey in Greece. J Community Health 2022. [PMID: 36242705 DOI: 10.1007/s10900-022-01144-x] [Reference Citation Analysis]
9 Gareayaghi N, Demirci M, Ozbey D, Dasdemir F, Dinc HO, Balkan II, Saribas S, Saltoglu N, Kocazeybek B. Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose. Vaccines (Basel) 2022;10. [PMID: 36298537 DOI: 10.3390/vaccines10101672] [Reference Citation Analysis]
10 Lin T, Zhao Z, Yang Z, Li B, Wei C, Li F, Jiang Y, Liu D, Yang Z, Sha F, Tang J. Hospital strain and Covid-19 fatality: analysis of English nationwide surveillance data.. [DOI: 10.1101/2022.09.27.22280401] [Reference Citation Analysis]
11 Shao W, Chen X, Zheng C, Liu H, Wang G, Zhang B, Li Z, Zhang W. Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Variants of Concern in Real-world: a Literature Review and Meta-analysis. Emerg Microbes Infect 2022;:1-75. [PMID: 36069511 DOI: 10.1080/22221751.2022.2122582] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Núñez NG, Schmid J, Power L, Alberti C, Krishnarajah S, Kreutmair S, Unger S, Blanco S, Konigheim B, Marín C, Onofrio L, Kienzler JC, Costa Pereira SD, Ingelfinger F, Pasinovich ME, Castelli JM, Vizzotti C, Schaefer M, Villar-vesga J, Merten CH, Sethi A, Wertheimer T, Lutz M, Vanoaica D, Sotomayor C, Gruppi A, Münz C, Cardozo D, Barbás G, Lopez L, Carreño P, Castro G, Raboy E, Gallego S, Morón G, Cervi L, Acosta Rodriguez EV, Maletto BA, Maccioni M, Becher B, InmunoCovidCba, InViV working group. Distinct immune signatures discriminate SARS-CoV-2 vaccine combinations.. [DOI: 10.1101/2022.09.05.22279572] [Reference Citation Analysis]
13 Deng J, Ma Y, Liu Q, Du M, Liu M, Liu J. Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2022;19. [PMID: 36078466 DOI: 10.3390/ijerph191710752] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Hartley GE, Edwards ES, Varese N, Boo I, Aui PM, Bornheimer SJ, Hogarth PM, Drummer HE, O’hehir RE, van Zelm MC. Double-dose mRNA vaccination to SARS-CoV-2 progressively increases recognition of variants-of-concern by Spike RBD-specific memory B cells.. [DOI: 10.1101/2022.08.03.502703] [Reference Citation Analysis]
15 Roth N, Schön J, Hoffmann D, Thran M, Thess A, Mueller SO, Petsch B, Rauch S. Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody Responses. Vaccines 2022;10:1251. [DOI: 10.3390/vaccines10081251] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Cheng H, Peng Z, Si S, Alifu X, Zhou H, Chi P, Zhuang Y, Mo M, Yu Y. Neutralization Activity against SARS-CoV-2 Variants after Booster Vaccination in Populations without COVID-19: A Meta-Analysis. Vaccines (Basel) 2022;10:1101. [PMID: 35891263 DOI: 10.3390/vaccines10071101] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Kontopoulou K, Nakas CT, Belai C, Papazisis G. Antibody Titers After a Third Dose of the SARS-CoV-2 BNT162b2 Vaccine in immunocompromised adults in Greece: is a fourth dose necessary? J Med Virol 2022. [PMID: 35739059 DOI: 10.1002/jmv.27954] [Reference Citation Analysis]
18 Eugenia Toledo-romaní M, García-carmenate M, Valenzuela-silva C, Baldoquín-rodríguez W, Martínez-pérez M, Rodríguez-gonzález M, Paredes-moreno B, Mendoza-hernández I, González-mujica R, Samón-tabio O, Velazco-villares P, Bacallao-castillo JP, Licea-martín E, Rodríguez-ortega M, Herrera-marrero N, Caballero-gonzález E, Egües-torres L, Duartes-gonzález R, García-blanco S, Pérez-cabrera S, Huete-ferreira S, Idalmis-cisnero K, Fonte-galindo O, Meliá-pérez D, Rojas-remedios I, Doroud D, Gouya MM, Biglari A, Van der Stuyft P, Fernández-castillo S, Climent-ruiz Y, Valdes-balbín Y, García-rivera D, Verez-bencomo V, the SOBERANA Phase 3 team. Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-PLUS: double-blind, randomised, placebo-controlled phase 3 clinical trial.. [DOI: 10.1101/2021.10.31.21265703] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
19 Roth N, Schön J, Hoffmann D, Thran M, Thess A, Mueller SO, Petsch B, Rauch S. Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homogeneous and heterogenous neutralising antibody responses.. [DOI: 10.1101/2021.05.13.443734] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]